Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Science Advances|March 31, 2023
Light-activated macromolecular phase separation modulates transcription by reconfiguring chromatin interactionsYoon Jung Kim, Michael Lee, Yi-Tsang Lee, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitorScott Throner, Tianshu Feng, Jannik N Andersen, et al.
Molecular Cancer Therapeutics|May 6, 2025
CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumorsKatherine Lazarides, Justin L Engel, Michele Meseonznik, et al.
Biotechnology and Bioengineering|December 25, 2021
Restoration of DNA repair mitigates genome instability and increases productivity of Chinese hamster ovary cellsPhilipp N Spahn, Xiaolin Zhang, Qing Hu, et al.
Cancer Cell|July 16, 2015
MYC Is a Major Determinant of Mitotic Cell FateCaroline Topham, Anthony Tighe, Peter Ly, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2023
SETD2 safeguards the genome against isochromosome formationFrank M Mason, Emily S Kounlavong, Anteneh T Tebeje, et al.
Nature|December 28, 2020
Chromothripsis drives the evolution of gene amplification in cancerOfer Shoshani, Simon F Brunner, Rona Yaeger, et al.
Blood|March 22, 2023
Structural variation cooperates with permissive chromatin to control enhancer hijacking-mediated oncogenic transcriptionGiovanni A Botten, Yuannyu Zhang, Kseniia Dudnyk, et al.
Molecular Cancer Therapeutics|October 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in CancerAntoine Simoneau, Justin L Engel, Madhavi Bandi, et al.
Cancer Research|September 7, 2022
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient GlioblastomaJulie A Shields, Samuel R Meier, Madhavi Bandi, et al.
Pageof 6